Press Release November 16, 2020

AMAG Pharmaceuticals Completes $500 Million Sale To Covis Group

The M&A and Life Sciences teams advised AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) on its sale to Covis Group S.à r.l. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.

AMAG is a commercial-stage biopharmaceutical company focused on bringing innovative products to patients with unmet medical needs. Covis is a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses. The addition of AMAG's category leading treatments and development-stage assets in women's health and hematology/oncology supports the execution of Covis' strategic vision to enhance the company's ability to impact the lives of patients by expanding its portfolio of 'best in class' products in attractive new therapeutic areas.

The Goodwin team was led by Stuart Cable, Jacqueline Mercier, and Lillian Kim, and included Chukwudi Udeogalanya, Will Stanton, Hayden Hutto, Sarah Bock, Morgan Frisoli, Jennifer Bralower, Reid Bagwell, Janet Andolina, Alex Plaum, Andrea Murino, Kirby Lewis, Matt Wheatley, Deborah Birnbach, Adam Slutsky, Jennifer Luz, Jim Barri, Theresa Kavanaugh, Megan Gustafson, Rich Matheny, James Brower, Justin Pierce, Jennifer Fay, Caroline Galiatsos, and Brian Mukherjee, with invaluable assistance from Shaleena Alli-Rampersad.

For more details, read the press release and articles in BioSpace, BioPharma Dive, and Barron’s.